The “difficult decision” was made “in order to protect other vital NHS services”, the National Institute for Health and Care ...
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...
Other work primarily only included glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among individuals with substance use disorders. We also compared GLP-1 RAs to metformin and ...